In addition, as depleting USP17 in NSCLC cells harboring EGFR activating mutations triggers their apoptosis, this indicates inhibiting USP17 may be of particular benefit in these tumors, which represent at least 10% of all NSCLC patients [17]. Here, USP17L2 is linked to non-small cell lung carcinoma.